Literature DB >> 19888316

Dementia: Does depression predict donepezil response in MCI?

Cornelius Katona.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19888316     DOI： 10.1038/nrneurol.2009.164

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  10 in total

Review 1.  Donepezil for mild cognitive impairment.

Authors:  J Birks; L Flicker
Journal:  Cochrane Database Syst Rev       Date:  2006-07-19

2.  Vitamin E and donepezil for the treatment of mild cognitive impairment.

Authors:  Ronald C Petersen; Ronald G Thomas; Michael Grundman; David Bennett; Rachelle Doody; Steven Ferris; Douglas Galasko; Shelia Jin; Jeffrey Kaye; Allan Levey; Eric Pfeiffer; Mary Sano; Christopher H van Dyck; Leon J Thal
Journal:  N Engl J Med       Date:  2005-04-13       Impact factor: 91.245

3.  International Psychogeriatric Association consensus statement on defining and measuring treatment benefits in dementia.

Authors:  Cornelius Katona; Gill Livingston; Claudia Cooper; David Ames; Henry Brodaty; Edmond Chiu
Journal:  Int Psychogeriatr       Date:  2007-03-27       Impact factor: 3.878

4.  Prevalent depressive symptoms as a risk factor for conversion to mild cognitive impairment in an elderly Italian cohort.

Authors:  Giovanni Ravaglia; Paola Forti; Anna Lucicesare; Elisa Rietti; Nicoletta Pisacane; Erminia Mariani; Edoardo Dalmonte
Journal:  Am J Geriatr Psychiatry       Date:  2008-10       Impact factor: 4.105

5.  The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease.

Authors:  C Holmes; D Wilkinson; C Dean; S Vethanayagam; S Olivieri; A Langley; N D Pandita-Gunawardena; F Hogg; C Clare; J Damms
Journal:  Neurology       Date:  2004-07-27       Impact factor: 9.910

6.  Depressive symptoms, vascular risk factors and mild cognitive impairment. The Italian longitudinal study on aging.

Authors:  Francesco Panza; Alessia D'Introno; Anna M Colacicco; Cristiano Capurso; Angelo Del Parigi; Richard J Caselli; Orlando Todarello; Vincenza Pellicani; Andrea Santamato; Pierluigi Scapicchio; Stefania Maggi; Emanuele Scafato; Claudia Gandin; Antonio Capurso; Vincenzo Solfrizzi
Journal:  Dement Geriatr Cogn Disord       Date:  2008-03-05       Impact factor: 2.959

7.  Depressive symptoms, vascular disease, and mild cognitive impairment: findings from the Cardiovascular Health Study.

Authors:  Deborah E Barnes; George S Alexopoulos; Oscar L Lopez; Jeff D Williamson; Kristine Yaffe
Journal:  Arch Gen Psychiatry       Date:  2006-03

8.  Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study.

Authors:  Howard H Feldman; Steven Ferris; Bengt Winblad; Nikolaos Sfikas; Linda Mancione; Yunsheng He; Sibel Tekin; Alistair Burns; Jeffrey Cummings; Teodoro del Ser; Domenico Inzitari; Jean-Marc Orgogozo; Heinrich Sauer; Philip Scheltens; Elio Scarpini; Nathan Herrmann; Martin Farlow; Steven Potkin; H Cecil Charles; Nick C Fox; Roger Lane
Journal:  Lancet Neurol       Date:  2007-06       Impact factor: 44.182

9.  Donepezil delays progression to AD in MCI subjects with depressive symptoms.

Authors:  P H Lu; S D Edland; E Teng; K Tingus; R C Petersen; J L Cummings
Journal:  Neurology       Date:  2009-06-16       Impact factor: 9.910

Review 10.  Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials.

Authors:  Roberto Raschetti; Emiliano Albanese; Nicola Vanacore; Marina Maggini
Journal:  PLoS Med       Date:  2007-11-27       Impact factor: 11.069
  10 in total
  2 in total

Review 1.  Pulsed intravenous administration of scopolamine produces rapid antidepressant effects and modest side effects.

Authors:  Maura L Furey; Carlos A Zarate
Journal:  J Clin Psychiatry       Date:  2013-08       Impact factor: 4.384

Review 2.  Cholinergic regulation of mood: from basic and clinical studies to emerging therapeutics.

Authors:  Stephanie C Dulawa; David S Janowsky
Journal:  Mol Psychiatry       Date:  2018-08-17       Impact factor: 15.992
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.